Hangzhou Tigermed Consulting Statistics

Total Valuation

Hangzhou Tigermed Consulting has a market cap or net worth of CNY 51.00 billion. The enterprise value is 55.15 billion.

Market Cap	51.00B
Enterprise Value	55.15B

Important Dates

The next estimated earnings date is Thursday, October 24, 2024.

Earnings Date	Oct 24, 2024
Ex-Dividend Date	Jul 12, 2024

Share Statistics

Hangzhou Tigermed Consulting has 861.29 million shares outstanding. The number of shares has increased by 0.15% in one year.

Shares Outstanding	861.29M
Shares Change (YoY)	+0.15%
Shares Change (QoQ)	-1.38%
Owned by Insiders (%)	27.76%
Owned by Institutions (%)	37.01%
Float	622.16M

Valuation Ratios

The trailing PE ratio is 48.37 and the forward PE ratio is 30.69. Hangzhou Tigermed Consulting's PEG ratio is 3.47.

PE Ratio	48.37
Forward PE	30.69
PS Ratio	7.76
PB Ratio	2.61
P/FCF Ratio	91.43
PEG Ratio	3.47

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 30.43, with an EV/FCF ratio of 92.90.

EV / Earnings	48.84
EV / Sales	7.84
EV / EBITDA	30.43
EV / EBIT	36.94
EV / FCF	92.90

Financial Position

The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.17.

Current Ratio	1.43
Quick Ratio	1.41
Debt / Equity	0.17
Debt / EBITDA	2.24
Debt / FCF	6.85
Interest Coverage	11.10

Financial Efficiency

Return on equity (ROE) is 5.41% and return on invested capital (ROIC) is 3.37%.

Return on Equity (ROE)	5.41%
Return on Assets (ROA)	3.11%
Return on Capital (ROIC)	3.37%
Revenue Per Employee	752,186
Profits Per Employee	120,813
Employee Count	9,701
Asset Turnover	0.23
Inventory Turnover	178.10

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +25.39% in the last 52 weeks. The beta is 0.84, so Hangzhou Tigermed Consulting's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	+25.39%
50-Day Moving Average	53.25
200-Day Moving Average	51.56
Relative Strength Index (RSI)	57.98
Average Volume (20 Days)	12,331,113

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hangzhou Tigermed Consulting had revenue of CNY 7.03 billion and earned 1.13 billion in profits. Earnings per share was 1.30.

Revenue	7.03B
Gross Profit	2.70B
Operating Income	1.49B
Pretax Income	1.58B
Net Income	1.13B
EBITDA	1.69B
EBIT	1.49B
Earnings Per Share (EPS)	1.30

Full Income Statement

Balance Sheet

The company has 3.22 billion in cash and 4.07 billion in debt, giving a net cash position of -854.32 million or -0.99 per share.

Cash & Cash Equivalents	3.22B
Total Debt	4.07B
Net Cash	-854.32M
Net Cash Per Share	-0.99
Equity (Book Value)	24.07B
Book Value Per Share	24.10
Working Capital	2.31B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 952.73 million and capital expenditures -359.04 million, giving a free cash flow of 593.68 million.

Operating Cash Flow	952.73M
Capital Expenditures	-359.04M
Free Cash Flow	593.68M
FCF Per Share	0.69

Full Cash Flow Statement

Margins

Gross margin is 38.36%, with operating and profit margins of 21.24% and 16.06%.

Gross Margin	38.36%
Operating Margin	21.24%
Pretax Margin	22.46%
Profit Margin	16.06%
EBITDA Margin	24.07%
EBIT Margin	21.24%
FCF Margin	8.44%

Dividends & Yields

This stock pays an annual dividend of 0.57, which amounts to a dividend yield of 0.85%.

Dividend Per Share	0.57
Dividend Yield	0.85%
Dividend Growth (YoY)	3.27%
Years of Dividend Growth	3
Payout Ratio	53.32%
Buyback Yield	-0.15%
Shareholder Yield	0.70%
Earnings Yield	2.07%
FCF Yield	1.09%

Dividend Details

Stock Splits

The last stock split was on July 1, 2019. It was a forward split with a ratio of 1.5.

Last Split Date	Jul 1, 2019
Split Type	Forward
Split Ratio	1.5

Scores

Hangzhou Tigermed Consulting has an Altman Z-Score of 5.34.

Altman Z-Score	5.34
Piotroski F-Score	n/a